Enliven Therapeutics, Inc. (ELVN)

NASDAQ • Healthcare

$41.52

-$0.4 (-1.0%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$41.49

Previous Close$41.52

Day Range$40.82 - $41.64

Avg. Volume (3M)1.4M

Market Cap$3B

52 Week Range

$14.79$62.32

Next EarningsIn 17 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$105.9M

EPS (TTM)

-$1.64

ROA (TTM)

-11.64%

Current Ratio

64.07

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+7.5%Q3 2025-$0.49

+25.6%Q4 2025-$0.32

-14.3%Q1 2026-$0.48

+13.6%Q2 2026-$0.38

-26.6%Q3 2026-$0.49

Nov 11

in 17 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -26.6%

Enliven Therapeutics’ earnings missed expectations in the second fiscal quarter of 2026, with reported August 5, 2026 preliminary results showing EPS of $-0.49 trailed the $-0.39 estimate (-27%) and matched the $-0.49 loss per share a year ago (+0.0% YoY). The company posted a GAAP net loss of roughly $32.5 million, down 28.2% from about $25.3 million a year earlier, alongside a GAAP operating loss of around $37.2 million. Cash burn remained evident, with negative operating cash flow of about $18.5 million for the quarter. For the next period, consensus calls for EPS of $-0.43.

Next report — what to expect

Enliven Therapeutics, Inc. (ELVN) reports next on November 11, 2026. Wall Street’s consensus calls for EPS of -$0.48. The company has beaten EPS in 5 of its 8 most recent quarters, so traders will be watching whether results and commentary align with that recent pattern.

View full earnings history

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. is a NASDAQ-listed Biotechnology company in the healthcare sector that is in the clinical development stage. The company discovers and advances small molecule cancer therapies, giving it the profile of an early-stage drug developer rather than a commercial biopharma business.

Name

Enliven Therapeutics, Inc.

CEO

Richard A. Fair

Website

www.enliventherapeutics.com

Industry

Healthcare

Employees

Today's Snapshot

AI-generated

The day ended with ELVN 1% lower at 41.52, in line with a weaker sector. Shares changed hands at about half of its usual level.

Trading Volume

Below 10d avg (1.4M)

792.7K

vs S&P 500 Today

Moderate Underperformance

-0.46%

Updated: October 23, 2026 at 20:11 UTC

Technical Indicators

2 Buy3 Neutral3 Sell

ELVN exhibits a predominantly negative technical picture despite mixed short-term signals. The trend is strong to the downside as shown by a high ADX, and momentum is muted with RSI below 40 while MACD is not showing bullish conviction. Price trades under several medium-term averages and beneath the 200-day simple moving average, and volatility is relatively elevated as indicated by a higher ATR; however, on-balance volume remains constructive, creating some divergence. Technical takeaway: the weight of evidence supports a Sell stance.

All signals